Home Cart Sign in  
Chemical Structure| 52806-53-8 Chemical Structure| 52806-53-8

Structure of Hydroxyflutamide
CAS No.: 52806-53-8

Chemical Structure| 52806-53-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Hydroxyflutamide is a derivative of the synthetic steroid ethisterone, that suppresses the production of gonadotrophins, and has some weak androgenic effects.

Synonyms: HFT; Hydroxyniphtholide; 2-HOF

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Hydroxyflutamide

CAS No. :52806-53-8
Formula : C11H11F3N2O4
M.W : 292.21
SMILES Code : CC(C)(O)C(NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1)=O
Synonyms :
HFT; Hydroxyniphtholide; 2-HOF
MDL No. :MFCD00563126
InChI Key :YPQLFJODEKMJEF-UHFFFAOYSA-N
Pubchem ID :91649

Safety of Hydroxyflutamide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00001266 Prostatic Neoplasm Phase 2 Completed - United States, Maryland ... More >> National Cancer Institute (NCI) Bethesda, Maryland, United States, 20892 Less <<
NCT03348527 Prostate Cancer Phase 2 Recruiting May 2019 Canada, Nova Scotia ... More >> Nova Scotia Health Authority Recruiting Halifax, Nova Scotia, Canada, B3H 2Y9 Contact: Noreen Miller    905-473-5876    noreen.miller@nshealth.ca    Principal Investigator: Ricardo Rendon, MD          Canada, Ontario Jonathan Giddens Medicine Professional Corporation Recruiting Brampton, Ontario, Canada, L6T 4S5 Contact: Sangeeta Madaan    905-874-0092    sangeetamadaan@gmail.com    Principal Investigator: Jonathan Giddens, MD          G. Kenneth Jansz Medicine Professional Corporation Recruiting Burlington, Ontario, Canada, L7N 3V2 Contact: Zena Al-Mudaris    905-681-9149    janszresearch@gmail.com    Principal Investigator: G. Kenneth Jansz, MD          The Fe/Male Health Centres Recruiting Oakville, Ontario, Canada, L6H 3 P1 Contact: Rupi Dhaliwal    905-338-3130 ext 2    rdhaliwal@malehealth.com    Principal Investigator: Peter Incze, MD          Sub-Investigator: Richard Casey, MD          Sunnybrook Health Sciences Centre Recruiting Toronto, Ontario, Canada, M4N 3M5 Contact: Marlene Kebabdjian    416-480-4600 ext 2890    marlene.kebabdjian@sunnybrook.ca    Principal Investigator: Laurence Klotz, MD          Canada, Quebec CIUSSS de l'Estrie - CHUS Recruiting Sherbrooke, Quebec, Canada, J1H 5N4 Contact: Elsie Morneau    819-346-1110 ext 12827    emorneau.chus@ssss.gouv.qc.ca    Principal Investigator: Patrick Richard, MD          Finland Helsinki University Hospital Recruiting Helsinki, Finland, FIN-00100 Contact: Antti Rannikko, MD       antti.rannikko@hus.fi    Principal Investigator: Antti Rannikko, MD          Tampere University Hospital Recruiting Tampere, Finland, FI-33521 Contact: Maria Pekki    358 (0)3 3116 6829    maria.pekki@pshp.fi    Principal Investigator: Teuvo Tammela, MD          Lithuania Hospital of Lithuanian University of Health Sciences Recruiting Kaunas, Lithuania, 50161 Contact: Kestutis Vaiciunas    370 610 31163    kvaic@yahoo.co.uk    Principal Investigator: Mindaugas Jievaltas, MD          National Cancer Institute - Oncourology Department Recruiting Vilnius, Lithuania, 08660 Contact: Donatas Slaitas, MD    370 603 62200    donates.slaitas@gmail.com    Principal Investigator: Albertas Ulys, MD Less <<
NCT00913263 Prostate Cancer Phase 1 Phase 2 Completed - Finland ... More >> Tampere University Hospital Tampere, Finland, 33520 Tampere University Hospital Tampere, Finland Less <<
NCT00913263 - Completed - -
NCT02341404 Prostate Cancer Phase 2 Completed - Finland ... More >> Dept of Urology, University Hospital Tampere, Finland Sweden Dept of Urology, University Hospital Uppsala, Sweden, 756 53 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.42mL

0.68mL

0.34mL

17.11mL

3.42mL

1.71mL

34.22mL

6.84mL

3.42mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories